Joanna R. J.
- Country
- Poland
- Department
- Klinika Nowotworów Układu Chłonnego
Research Overview
- Phase 3 Randomized Study of Tirabrutinib Versus Rituximab-Temozolomide in Relapsed/Refractory Primary Central Nervous System Lymphoma
- Phase III Randomized Open‑Label Study of Cevostamab Combination Therapy Versus Standard of Care in Relapsed/Refractory Multiple Myeloma After 1‑3 Prior Lines
- Phase II MRD‑guided Trial of Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 203 of 383 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in developing treatments for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases. Their research encompasses novel therapeutic combinations including elranatamab, teclistamab, and belantamab mafodotin.
- Post-transplant treatment strategies
- Novel therapeutic combinations
- Treatment-resistant myeloma
B-Cell Lymphoma Studies
Extensive work in B-cell lymphoma therapeutics, particularly focusing on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The research includes innovative approaches using targeted therapies and combination treatments.
- Advanced B-cell malignancies
- Novel therapeutic antibodies
- Combination chemotherapy protocols
T-Cell Lymphoma Expertise
Specialized research in T-cell lymphoma treatments, including studies on peripheral T-cell lymphoma and innovative therapeutic approaches for advanced T-cell lymphomas.
- Cutaneous T-cell lymphoma treatments
- Novel drug combinations
- Targeted immunotherapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.